SeekingAlpha · Sep 8, 2026
MoonLake Immunotherapeutics: The Bull Case Does Not Require Clinical Supremacy
MoonLake Immunotherapeutics (MLTX) investment outlook: sonelokimab durability, HS regulatory path, cash runway to 2028, and key risks.
ML
NASDAQ · MLTX
MoonLake Immunotherapeutics
Healthcare · Biotechnology
$12.51
Down-$0.67 (-5.08%)
Updated Sep 12, 2026, 3:36 AM
SID Score
5.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 895.62M
- P/E ratio
- -5.04
- Dividend yield
- 0.00%
- 52-week range
- $5.95 – $62.75
- Volume
- 2.39M
- Avg. volume
- 5.18M
Price performance
MLTX price history
1M range · 20 trading sessions · Daily adjusted prices
MLTX closed at $12.51 after 20 trading sessions, down 24.04% for the selected period.
- Last close
- $12.51
- Period change
- -24.04%
- Period low
- $12.51
- Period high
- $16.74
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 11, 2026 | $13.33 | $13.55 | $12.4724 | $12.51 | 2.39M |
| Sep 10, 2026 | $13.58 | $13.62 | $13.12 | $13.18 | 1.22M |
| Sep 9, 2026 | $14.90 | $15.00 | $13.66 | $13.72 | 1.69M |
| Sep 8, 2026 | $14.80 | $15.43 | $14.69 | $14.94 | 1.46M |
| Sep 4, 2026 | $15.06 | $15.24 | $14.87 | $15.01 | 1.43M |
| Sep 3, 2026 | $15.08 | $15.45 | $14.98 | $15.19 | 841.99K |
| Sep 2, 2026 | $15.14 | $15.47 | $14.85 | $15.06 | 1.19M |
| Sep 1, 2026 | $14.99 | $15.31 | $14.83 | $15.13 | 662.55K |
| Aug 31, 2026 | $14.94 | $15.11 | $14.63 | $15.05 | 1.02M |
| Aug 28, 2026 | $15.60 | $15.765 | $14.965 | $14.99 | 700.46K |
| Aug 27, 2026 | $15.62 | $15.78 | $15.47 | $15.53 | 1.1M |
| Aug 26, 2026 | $15.50 | $15.765 | $15.335 | $15.62 | 1M |
| Aug 25, 2026 | $15.54 | $15.97 | $15.525 | $15.56 | 819.51K |
| Aug 24, 2026 | $15.68 | $15.69 | $15.23 | $15.37 | 1.14M |
| Aug 21, 2026 | $15.99 | $16.10 | $15.58 | $15.76 | 1.35M |
| Aug 20, 2026 | $16.53 | $16.74 | $15.545 | $15.87 | 1.37M |
| Aug 19, 2026 | $16.57 | $16.8559 | $16.1185 | $16.74 | 1.45M |
| Aug 18, 2026 | $16.36 | $16.65 | $16.14 | $16.34 | 825.73K |
| Aug 17, 2026 | $16.44 | $16.66 | $16.20 | $16.35 | 1.2M |
| Aug 14, 2026 | $16.31 | $16.67 | $16.30 | $16.47 | 981.6K |
Latest MLTX news
The latest Smart Investors Daily articles mentioning MLTX.
Stock researchCompany · Overview
MLTX research
Overview
Company profile and research snapshot.
Company profile
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $17.29
- Implied upside
- —
- Analysts
- 24
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 13, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 20, 2026 | HC Wainwright & Co. | Buy | — |
| Jul 1, 2026 | Leerink Partners | Outperform | — |
| Jun 9, 2026 | BTIG | Buy | — |
| Jun 8, 2026 | HC Wainwright & Co. | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 13, 2026
HC Wainwright & Co. Maintains Buy on MoonLake, Raises Price Target to $50
HC Wainwright & Co. analyst Raghuram Selvaraju maintains MoonLake (NASDAQ:MLTX) with a Buy and raises the price target from $45 to $50.
Yahoo · Aug 10, 2026
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Phase 3 Trial – Retail Shrugs Off Premarket Slide, Says ‘Pipeline Is Intact’
At week 16, 42.1% of patients on Sonelokimab achieved at least a 50% improvement in psoriatic arthritis symptoms, meeting the trial’s primary endpoint.
Benzinga · Aug 10, 2026
MoonLake’s Psoriatic Arthritis Drug Shows Promise In Late-Stage Study
MoonLake Immunotherapeutics (MLTX) announces positive Phase 3 psoriatic arthritis trial results. Cash runway backed through mid-2028.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
